Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Central Serous Chorioretinopathy Clinical Trial

Official title:

Comparative Study on the Efficacy of the Combination of Micropulse Laser With or Without Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinal Disease

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06468540
• Other study ID #: IIT-2024-04-376
• Status: Not yet recruiting
• Start date: June 15, 2024
• Est. completion date: December 15, 2025

Study information

• Verified date: June 2024
• Source: Beijing Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: December 15, 2025
• Est. primary completion date: June 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age >18 years old.

• The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.

• Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.

• Patients had follow-up data before and after treatment for 1 month and at least 6 months.

Exclusion Criteria:

• Patients with other fundus diseases or refractive interstitial opacity.

• During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.

• Various reasons led to incomplete patient data.

Related Conditions & MeSH terms

• Central Serous Chorioretinopathy
• Photodynamic Therapy

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BCVA	Best-corrected visual acuity using logMAR	1 month and 6 months
Primary	CRT	Central retinal thickness on OCT	1 month and 6 months
Secondary	SFCT	subfoveal choroidal thickness on OCTA	1 month and 6 months